Patents by Inventor Luis Javier Cruz
Luis Javier Cruz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11185600Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultrasound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.Type: GrantFiled: September 14, 2013Date of Patent: November 30, 2021Assignee: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMInventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo, Christoffel Leendert De Korte
-
Publication number: 20200230164Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as ? Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3-dendritic cells.Type: ApplicationFiled: January 24, 2020Publication date: July 23, 2020Inventors: Francois TROTTEIN, Christelle FAVEEUW, Elodie MACHO FERNANDEZ, Luis Javier CRUZ RICONDO
-
Publication number: 20180258140Abstract: The present invention relates to targeted microcapsules comprising a skin aging compound to target fibroblast with a peptide, which is a FGF receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule. It also relates to the use of said microcapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous effects of skin aging and to the cosmetic compositions comprising said microcapsules. The invention also relates to the FGF receptor agonist peptide coupled to the microcapsule.Type: ApplicationFiled: February 24, 2016Publication date: September 13, 2018Inventors: Marisabel Mourelle Mancini, Luis Javier Cruz Ricondo, Magdalena Carceller Margeli
-
Patent number: 9745346Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.Type: GrantFiled: March 10, 2015Date of Patent: August 29, 2017Assignee: INFINITEC ACTIVOS S.LInventors: Marisabel Mourelle Mancini, Magdalena Carceller Margeli, Luis Javier Cruz Ricondo
-
Publication number: 20170081364Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.Type: ApplicationFiled: March 10, 2015Publication date: March 23, 2017Applicant: INFINITEC ACTIVOS S.L.Inventors: Marisabel Mourelle Mancini, Magdalena Carceller Margeli, Luis Javier Cruz Ricondo
-
Publication number: 20150374734Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as ? Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.Type: ApplicationFiled: February 20, 2014Publication date: December 31, 2015Inventors: Francois TROTTEIN, Christelle FAVEEUW, Elodie MACHO FERNANDEZ, Luis Javier CRUZ RICONDO
-
Publication number: 20150250905Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultra-sound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.Type: ApplicationFiled: September 14, 2013Publication date: September 10, 2015Inventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo
-
Publication number: 20100323021Abstract: The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle.Type: ApplicationFiled: January 30, 2009Publication date: December 23, 2010Applicant: PHARMA MAR, S.A.Inventors: Leticia Hosta, Mateu Pla, Luis Javier Cruz, Marcelo Kogan, Fernando Albericio
-
Publication number: 20090181424Abstract: A mammalian expression vector that is a murine CMV promoter and the first intron of the major immediate early gene of the human cytomegalovirus. There are mammalian host cells containing the expression vector. There is also a process for the production of recombinant protein by using the expression vector.Type: ApplicationFiled: April 20, 2006Publication date: July 16, 2009Inventors: Fernando Albericio, Luis Javier Cruz, Fayna Garcia-Martin, Judit Tulla-Puche
-
Publication number: 20090171068Abstract: A method for solid phase synthesis of Thymosin ?1 is devised.Type: ApplicationFiled: May 4, 2006Publication date: July 2, 2009Inventors: Fernando Albericio, Luis Javier Cruz, Yesica Garcia Ramos, Judit Tulla-Puche
-
Publication number: 20090104223Abstract: The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.Type: ApplicationFiled: October 10, 2007Publication date: April 23, 2009Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
-
Publication number: 20040202676Abstract: The present invention is related to the method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.Type: ApplicationFiled: March 1, 2004Publication date: October 14, 2004Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
-
Patent number: 6355414Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.Type: GrantFiled: January 6, 2000Date of Patent: March 12, 2002Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo PiƱol